Changes in Hong Kong stocks | Xuanzhu Bio-B (02575) rose more than 7%; medical insurance implementation of piroxilil tablets is expected to significantly improve access to pyroxil

Zhitongcaijing · 4d ago

The Zhitong Finance App learned that Xuanzhu Bio-B (02575) rose more than 7%. As of press release, it had risen 6.95% to HK$58.45, with a turnover of HK$10.671 million.

According to the news, on December 7, 2025, the National Medical Security Administration announced the results of the 2025 national medical insurance drug catalogue adjustment. The Class 1 innovative drug developed independently by Xuanzhu Biotech and the CDK4/6 inhibitor pyroxil tablets were successfully included in the catalogue, bringing new medical insurance reimbursement benefits to patients with advanced breast cancer. On January 1, 2026, the national health insurance for pirosilil was officially implemented, which is expected to significantly improve the accessibility of piroxilil and effectively reduce the financial burden on patients.